Based on the above description, blocking PD-1 seems to be more effective than inhibiting PD-L1 or PD-L2, because it blunts all the pathways, as observed in non-small cell lung cancer (NSCLC) patients [52]. This evidence concerns the gene PDCD1LG2 and non-small cell lung carcinoma.